Codexis (CDXS) Scheduled to Post Quarterly Earnings on Thursday

Codexis (NASDAQ:CDXS) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Codexis has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Codexis (NASDAQ:CDXS) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.18. The firm had revenue of $26.56 million during the quarter, compared to analyst estimates of $24.73 million. Codexis had a negative net margin of 108.69% and a negative return on equity of 47.58%. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Trading Down 3.4 %

Shares of CDXS opened at $2.80 on Thursday. The firm has a market capitalization of $196.84 million, a P/E ratio of -2.52 and a beta of 2.01. Codexis has a 12-month low of $1.45 and a 12-month high of $4.91. The firm has a fifty day moving average price of $3.32 and a 200-day moving average price of $2.72.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CDXS. StockNews.com raised shares of Codexis to a “sell” rating in a research note on Tuesday, March 5th. Benchmark raised shares of Codexis from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Codexis presently has a consensus rating of “Hold” and a consensus price target of $6.80.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.